Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

4860 - An Investigator Initiated, Open Label, Randomized, Controlled, Multicentric Study, to assess the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR ) concurrent with Cisplatin and Radiotherapy (RT) in histologically documented Squamous Cell Carcinoma of the Cervix


09 Sep 2017


Gynaecological cancers


Cytotoxic Therapy;  Surgical Oncology;  Radiation Oncology;  Cervical Cancer


Basavalingaiah Ajaikumar


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


B.S. Ajaikumar1, K. Swamy2, N. Radheshyam1, S. Patil1, H.P. Shashidhara3, M.S.A. Vishweshwara4, N.K. Rao2, Y. Madhavi4, N. Ravi5, R. Bilimagga2, R. Rao6, D. Pawar7

Author affiliations

  • 1 Medical Oncology, Healthcare Global Enterprises ltd., 560027 - BANGALORE/IN
  • 2 Radiation Oncology, Healthcare Global Enterprises ltd., 560027 - BANGALORE/IN
  • 3 Medical Oncology, HCG Bangalore Institute of Oncology Speciality Centre, 560027 - Bangalore/IN
  • 4 Radiation Oncology, Bharath Hospital and Institute of Oncology, 570017 - Mysore/IN
  • 5 Radiation Oncology, HCG Malnad Hospital Institute of Oncology, Shimoga/IN
  • 6 Healthcare Global Enterprises Ltd., CARE, HCG Foundation, 560027 - BANGALORE/IN
  • 7 Medical Affairs, Biocon Limited, 560100 - Bangalore/IN


Abstract 4860


EGFR inhibitors have proven to improve the efficacy of anticancer treatments in lung, colon, pancreas, or HNC. Results from studies show EGFR expression in cervical Ca to improve survival outcomes in the same. This study was designed to assess safety and efficacy of Nimotuzumab with concurrent cisplatin and RT in patients with Ca Cervix.


In this open-label randomized controlled multicentric study 100 patients with histologically confirmed Ca Cervix were recruited over a 4 year period with an equal allocation of 1:1 for intervention (Standard arm- concurrent CTRT (Cisplatin 40mg/m2 weekly IV +RT) plus 200mg weekly BIOMAB IV (n = 50) on same day of cisplatin infusion) vs. standard arm only (n = 50). At 2 years data were available for 39 patients in the intervention arm and 35 patients in standard arm. The size of the lesion was documented using CT/PETCT at baseline. The response was analyzed using RECIST criteria at the following treatment every 3 months for subsequent 2 years. Toxicity was assessed using CTCAE v4 toxicity criteria.


There were 74 evaluable patients at end of 2 years. The mean age was 49.6± 10.2 years. The complete response following treatment was seen in 37.8% (BIOMAB arm) of patients at two years following treatment compared to 38.2% in standard arm. However, progressive disease was seen more in standard arm (52.9%) compared to BIOMAB arm (35.1%). Best overall response was seen in 64.9% patients in the intervention arm compared to 47.1% patients in the standard arm at two years following treatment which is significant. At 2 years 60% progressed on standard arm compared to 37.5% in the intervention arm. The mean estimate of progression-free survival being 36 months vs. 56.5 months (BioMab arm) (Log rank Mantel-Cox χ2= 3.9, p = 0.05). Except for one patient with Biomab sensitivity, there was no additional toxicity compared to the standard arm.


Nimotuzumab appears to be safe and effective targeted therapy in cervical cancer patients with long-term benefits.

Clinical trial identification


Legal entity responsible for the study

Healthcare Global Enterprises Ltd.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.